# Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS)

> **NCT00654225** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2340 (estimated)

## Conditions studied

- Hypercholesterolemia
- Dyslipidaemia

## Interventions

- **DRUG:** Rosuvastatin
- **DRUG:** Atorvastatin

## Key facts

- **NCT ID:** NCT00654225
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** —
- **Final completion:** 2005-03
- **Target enrollment:** 2340 (ESTIMATED)
- **Last updated:** 2009-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00654225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00654225, "Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS)". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00654225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*